Hercules Capital Taps Bluestein as President/CEO

Hercules Capital has appointed Scott Bluestein as its chief executive officer and president, effective immediately.

Hercules Capital Amends Debt Facility for Tricida

Tricida has entered into an amendment to its existing debt facility with Hercules Capital. The amendment increases the total amount available under the debt facility to up to $200 million and extends the maturity of the loans thereunder. Tricida originally entered into a $100 million debt facility with Hercules Capital in February 2018.

Hercules Capital CEO Steps Down After Charge in College Admissions Scheme

Hercules Capital CEO Manuel Henriquez has voluntarily stepped aside as the firm’s chairman and CEO. According to Bloomberg, the news comes in the wake of Henriquez’s indictment by federal authorities because of his alleged involvement in the college admissions cheating scandal.

Hercules Capital Provides Up to $75MM Term Loan to Nabriva

Hercules Capital closed a term loan of up to $75 million for Nabriva Therapeutics, a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections.

Hercules Capital Upsizes FuelCell Facility to $25MM

Hercules Capital increased FuelCell Energy’s credit facility to $25 million and extended the maturity date to 2020.

Hercules Provides $75MM Facility to Mesoblast

Cell-based medicine developer Mesoblast entered into a $75 million non-dilutive, four-year credit facility with specialty finance company Hercules Capital.

Hercules Provides $75MM Sorrento Therapeutics Facility

Sorrento Therapeutics, a clinical-stage biopharmaceutical company developing treatments for cancer and other diseases, entered into a loan and security agreement with Hercules Capital for up to $75 million.